Company news

Starpharma Holdings Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Starpharma to commence DEP cabazitaxel phase 1/2 trial

January 31, 2018

VivaGel BV treatment clinical submission under rolling NDA

December 20, 2017

NDA submission for VivaGel BV in the US

November 21, 2017

VivaGel BV granted marketing approval in Australia

October 24, 2017

Starpharma and Peter Mac Cancer Centre awarded DEP Grant

October 9, 2017

AstraZeneca presents 1st DEP candidate as Bcl2/xL inhibitor

September 28, 2017

DEP docetaxel positive phase 1 results, phase 2 commences

September 22, 2017

Starpharma and Monash awarded STEM Business Fellowships

August 9, 2017

Successful VivaGel Phase 3 results and NDA planned for rBV

August 6, 2017

VivaGel BV phase 3 results timing and commercialisation

July 4, 2017

Starpharma sells Agrochemicals business to Agrium for $35M

June 13, 2017

DEP irinotecan outperforms irinotecan in cancer models

June 5, 2017

AstraZeneca DEP candidate advance triggers milestone to SPL

April 19, 2017

Ansell launches VivaGel condom in Canada

April 11, 2017

VivaGel BV phase 3 trials for prevention of BV completed

March 29, 2017

Shareholder Update January 2017

January 18, 2017

VivaGel BV granted QIDP and Fast Track designation by US FDA

January 11, 2017

Starpharma receives $3.5M R&D tax incentive refund

December 21, 2016

Starpharma signs license for VivaGel Condom in Iran

November 27, 2016

Additional Priostar Glyphosate Patent Allowed in US

October 27, 2016

Enrolment complete for Phase 3 VivaGel BV-R program

October 12, 2016

VivaGel condom receives regulatory approval in Canada

September 13, 2016

New DEP drug delivery program initiated with AstraZeneca

July 28, 2016

Starpharma signs license for a VivaGel condom in China

July 21, 2016

Appendix 4C - Quarterly Cashflow Reoprt

July 13, 2016

Starpharmas DEP eliminates cabazitaxel neutropenia

May 25, 2016

VivaGel active against Zika virus

May 5, 2016

DEP cabazitaxel shows complete, sustained tumour regression

April 4, 2016

Starpharma signs drug delivery license with AstraZeneca

March 30, 2016

Successful completion of VivaGel study sexually active women

March 30, 2016

Starpharma`s Bacterial Vaginosis Study gets FDA Clearance

March 30, 2016

Starpharma and Lilly Sign New Drug Delivery Collaboration

March 30, 2016

Starpharma`s partner SSL acquired by Reckitt Benckiser

March 30, 2016

Starpharma Expands Lilly Partnership

March 30, 2016

Response to an ASX Price Query

March 30, 2016

Starpharma secures FDA agreement on BV treatment Phase 3

March 30, 2016

Starpharma secures European (EMA) agreement on BV Phase 3

March 30, 2016

SPL: Terminates Reckitt agreement and signs with Ansell

March 30, 2016

SPL Commences VivaGel Bacterial Vaginosis Prevention Study

March 30, 2016

GSK awarded funds for dermal treatment with SPL`s dendrimers

March 30, 2016

Advances leading cancer therapeutic in drug delivery program

March 30, 2016

Starpharma`s VivaGel Phase 3 trials 60% enrolled

March 30, 2016

SPL`s dendrimers improve efficacy of docetaxel in animals

March 30, 2016

SPL receives FDA Special Protocol Assessment for BV Phase 3

March 30, 2016

SPL Commences pivotal phase 3 VivaGel BV treatment trials

March 30, 2016

Response to an ASX price query

March 30, 2016

Reports rapid advancement of drug delivery program

March 30, 2016

Starpharma to recoup $6 million cash for overseas R&D

March 30, 2016

Starpharma signs cancer drug agreement with AstraZeneca

March 30, 2016

Starpharma presenting at Bell Potter LifeScience Conference

March 30, 2016

← Newer news releases · Older news releases →

Decks

The 5 newest of 51 decks. Every deck is listed under its year.